Ericka L Fink1, Rachel P Berger, Robert S B Clark, Robert S Watson, Derek C Angus, Rudolph Richichi, Ashok Panigrahy, Clifton W Callaway, Michael J Bell, Patrick M Kochanek. 1. 1Department of Critical Care Medicine, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA. 2Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA. 3Department of Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA. 4Statistical Analysis and Measurement Consultants, Inc., Lanexa, VA. 5Department of Radiology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA. 6Department of Emergency Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA.
Abstract
OBJECTIVES: Morbidity and mortality in children with cardiac arrest largely result from neurologic injury. Serum biomarkers of brain injury can potentially measure injury to neurons (neuron-specific enolase), astrocytes (S100b), and axons (myelin basic protein). We hypothesized that serum biomarkers can be used to classify outcome from pediatric cardiac arrest. DESIGN: Prospective observational study. SETTING: Single tertiary pediatric hospital. PATIENTS: Forty-three children with cardiac arrest. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We measured serum neuron-specific enolase, S100b, and myelin basic protein on days 1-4 and 7 after cardiac arrest. We recorded demographics, details of the cardiac arrest and resuscitation, and Pediatric Cerebral Performance Category at hospital discharge and 6 months. We analyzed the association of biomarker levels at 24, 48, and 72 hours with favorable (Pediatric Cerebral Performance Category 1-3) or unfavorable (Pediatric Cerebral Performance Category 4-6) outcome and mortality. Forty-three children (49% female; mean age of 5.9 ± 6.3) were enrolled and 17 (40%) died. Serum S100b concentrations peaked earliest, followed by neuron-specific enolase and finally myelin basic protein. Serum neuron-specific enolase and S100b concentrations were increased in the unfavorable versus favorable outcome group and in subjects who died at all time points (all p < 0.05). Serum myelin basic protein at 24 and 72 hours correctly classified survival but not good versus poor outcome. Using best specificity, serum S100b and neuron-specific enolase had optimal positive and negative predictive values at 24 hours to classify both favorable versus unfavorable outcome and survival, whereas serum myelin basic protein's best accuracy occurred at 48 hours. Receiver operator curves for serum S100b and neuron-specific enolase to classify favorable versus unfavorable outcome at 6 months were superior to clinical variables. CONCLUSIONS: Preliminary data show that serum S100b, neuron-specific enolase, and myelin basic protein may aid in outcome classification of children surviving cardiac arrest.
OBJECTIVES: Morbidity and mortality in children with cardiac arrest largely result from neurologic injury. Serum biomarkers of brain injury can potentially measure injury to neurons (neuron-specific enolase), astrocytes (S100b), and axons (myelin basic protein). We hypothesized that serum biomarkers can be used to classify outcome from pediatric cardiac arrest. DESIGN: Prospective observational study. SETTING: Single tertiary pediatric hospital. PATIENTS: Forty-three children with cardiac arrest. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We measured serum neuron-specific enolase, S100b, and myelin basic protein on days 1-4 and 7 after cardiac arrest. We recorded demographics, details of the cardiac arrest and resuscitation, and Pediatric Cerebral Performance Category at hospital discharge and 6 months. We analyzed the association of biomarker levels at 24, 48, and 72 hours with favorable (Pediatric Cerebral Performance Category 1-3) or unfavorable (Pediatric Cerebral Performance Category 4-6) outcome and mortality. Forty-three children (49% female; mean age of 5.9 ± 6.3) were enrolled and 17 (40%) died. Serum S100b concentrations peaked earliest, followed by neuron-specific enolase and finally myelin basic protein. Serum neuron-specific enolase and S100b concentrations were increased in the unfavorable versus favorable outcome group and in subjects who died at all time points (all p < 0.05). Serum myelin basic protein at 24 and 72 hours correctly classified survival but not good versus poor outcome. Using best specificity, serum S100b and neuron-specific enolase had optimal positive and negative predictive values at 24 hours to classify both favorable versus unfavorable outcome and survival, whereas serum myelin basic protein's best accuracy occurred at 48 hours. Receiver operator curves for serum S100b and neuron-specific enolase to classify favorable versus unfavorable outcome at 6 months were superior to clinical variables. CONCLUSIONS: Preliminary data show that serum S100b, neuron-specific enolase, and myelin basic protein may aid in outcome classification of children surviving cardiac arrest.
Authors: Vinay M Nadkarni; Gregory Luke Larkin; Mary Ann Peberdy; Scott M Carey; William Kaye; Mary E Mancini; Graham Nichol; Tanya Lane-Truitt; Jerry Potts; Joseph P Ornato; Robert A Berg Journal: JAMA Date: 2006-01-04 Impact factor: 56.272
Authors: Akira Nishisaki; Joseph Sullivan; Bernhard Steger; Carey R Bayer; Dennis Dlugos; Richard Lin; Rebecca Ichord; Mark A Helfaer; Vinay Nadkarni Journal: Pediatr Crit Care Med Date: 2007-01 Impact factor: 3.624
Authors: E Su; M J Bell; P M Kochanek; S R Wisniewski; H Bayir; R S B Clark; P D Adelson; E C Tyler-Kabara; K L Janesko-Feldman; R P Berger Journal: Neurocrit Care Date: 2012-12 Impact factor: 3.210
Authors: Frank W Moler; Amy E Donaldson; Kathleen Meert; Richard J Brilli; Vinay Nadkarni; Donald H Shaffner; Charles L Schleien; Robert S B Clark; Heidi J Dalton; Kimberly Statler; Kelly S Tieves; Richard Hackbarth; Robert Pretzlaff; Elise W van der Jagt; Jose Pineda; Lynn Hernan; J Michael Dean Journal: Crit Care Med Date: 2011-01 Impact factor: 7.598
Authors: Jerry P Nolan; Robert W Neumar; Christophe Adrie; Mayuki Aibiki; Robert A Berg; Bernd W Bbttiger; Clifton Callaway; Robert S B Clark; Romergryko G Geocadin; Edward C Jauch; Karl B Kern; Ivan Laurent; W T Longstreth; Raina M Merchant; Peter Morley; Laurie J Morrison; Vinay Nadkarni; Mary Ann Peberdy; Emanuel P Rivers; Antonio Rodriguez-Nunez; Frank W Sellke; Christian Spaulding; Kjetil Sunde; Terry Vanden Hoek Journal: Int Emerg Nurs Date: 2009-08-05 Impact factor: 2.142
Authors: Kathleen L Meert; Amy Donaldson; Vinay Nadkarni; Kelly S Tieves; Charles L Schleien; Richard J Brilli; Robert S B Clark; Donald H Shaffner; Fiona Levy; Kimberly Statler; Heidi J Dalton; Elise W van der Jagt; Richard Hackbarth; Robert Pretzlaff; Lynn Hernan; J Michael Dean; Frank W Moler Journal: Pediatr Crit Care Med Date: 2009-09 Impact factor: 3.624
Authors: Alicia K Au; Michael J Bell; Ericka L Fink; Rajesh K Aneja; Patrick M Kochanek; Robert S B Clark Journal: Neurocrit Care Date: 2018-02 Impact factor: 3.210
Authors: Allan R de Caen; Marc D Berg; Leon Chameides; Cheryl K Gooden; Robert W Hickey; Halden F Scott; Robert M Sutton; Janice A Tijssen; Alexis Topjian; Élise W van der Jagt; Stephen M Schexnayder; Ricardo A Samson Journal: Circulation Date: 2015-11-03 Impact factor: 29.690
Authors: Tamil S Anthonymuthu; Elizabeth M Kenny; Andrew M Lamade; Hitesh Gidwani; Nicholas M Krehel; Amalea Misse; Xiaotian Gao; Andrew A Amoscato; Adam C Straub; Valerian E Kagan; Cameron Dezfulian; Hülya Bayır Journal: Crit Care Med Date: 2019-04 Impact factor: 7.598
Authors: Pelin Cengiz; Frank Zemlan; Jens C Eickhoff; Richard Ellenbogen; Jerry J Zimmerman Journal: Childs Nerv Syst Date: 2015-04-22 Impact factor: 1.475
Authors: Ericka L Fink; Rachel P Berger; Robert S B Clark; R Scott Watson; Derek C Angus; Ashok Panigrahy; Rudolph Richichi; Clifton W Callaway; Michael J Bell; Stefania Mondello; Ronald L Hayes; Patrick M Kochanek Journal: Resuscitation Date: 2016-02-06 Impact factor: 5.262
Authors: Alexis A Topjian; Sarah M Sánchez; Justine Shults; Robert A Berg; Dennis J Dlugos; Nicholas S Abend Journal: Pediatr Crit Care Med Date: 2016-06 Impact factor: 3.624
Authors: Michael A Ferguson; Robert M Sutton; Michael Karlsson; Fredrik Sjövall; Lance B Becker; Robert A Berg; Susan S Margulies; Todd J Kilbaugh Journal: J Bioenerg Biomembr Date: 2016-03-28 Impact factor: 2.945